UroAlerts - Prostate Cancer Weekly

May 26, 2026

Videos

Peer-to-Peer Clinical Conversations

Incorporating PSMA PETs in Registrational Trials "Presentation" - Alicia Morgans

Alicia Morgans

At the 2026 UCSF-UCLA PSMA Conference, Alicia Morgans describes ARASTEP, a 970-patient trial randomizing high-risk biochemical recurrence patients with PSMA PET-positive disease to darolutamide or placebo plus ADT following metastasis-directed SBRT.

CAPItello-281: Targeting the AKT Pathway in PTEN-Deficient mHSPC Presentation - Daniel George

Daniel George

Daniel George presents the CAPItello-281 study examining capivasertib combined with abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer.

Beyond the Abstracts

Targeted and Perilesional or Systematic Biopsies in Prostate Cancer: The TARGET Clinical Trial Protocol - Beyond the Abstract

A REtrospective Study to Describe the Real-World Treatment Landscape in Patients with Metastatic Castration-Resistant PROstate Cancer: REMPRO - Beyond the Abstract

Conference Coverage

AUA 2026: Radiographic Progression-free Survival as a Meaningful Endpoint in Metastatic Castration-Resistant Prostate Cancer (mCRPC): The TALAPRO-2 Randomized Clinical Trial

AUA 2026: Real-World Darolutamide Safety and Effectiveness in Patients with Nonmetastatic Castration-Resistant Prostate Cancer with Comorbidities and Concomitant Medications: Post Hoc Analyses at DAROL Interim Analysis 4 (IA4)

AUA 2026: Impact of Anemia and Its Management on Quality of Life in Metastatic Castration-resistant Prostate Cancer Patients Treated with Talazoparib Plus Enzalutamide

APCCC 2026: Debate: Patients with High-Risk Localized Prostate Cancer Need the Addition of an ARPI to Radiotherapy + Long-Term ADT – Against the Addition of ARPI to Radiotherapy + ADT

PSMA and Beyond 2026: Immunotherapy with Checkpoint Inhibitors and Beyond

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

Bladder activity of different PSMA PET radioligands and impact of furosemide.

Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancer.

Focal Signet Ring-Like Prostate Adenocarcinoma Detected on Microultrasound in the Setting of Negative Multiparametric Magnetic Resonance Imaging: A Case Report.

Moderate hypofractionated boost to the prostate with pelvic radiotherapy in high-risk prostate cancer (MOB-RT) - a phase 2 study: acute safety and quality of life outcomes.

Improving physical activity in men with prostate cancer through wearable devices and online education: Randomized controlled trial.

Baseline PSMA-ligand PET/CT as a predictive biomarker for early progression in metastatic castration-resistant prostate cancer patients undergoing [177Lu]Lu-PSMA-617 radioligand therapy.

Radioligand Therapy Hormone Combinations and the ENZA-p Trial.

Elective Nodal Radiotherapy in Localized Prostate Cancer: A Meta-Analysis.

Partial gland ablation for radio-recurrent prostate cancer: Short-term oncological and functional outcomes.

Frailty and Quality of Life in Low-Income, Uninsured Men with Prostate Cancer.

Racial and ethnic differences in prostate cancer screening outcomes in the United States: A secondary analysis of the prostate, lung, colorectal, and ovarian cancer trial.

Treatment and progression of patients in Sweden with metastatic castration-sensitive prostate cancer.

Transforming postoperative follow-up: telemedicine trends in radical prostatectomy patients.

Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.

Real-World Representation in Prostate Cancer Clinical Trials: Needs and Opportunities.

A Real-World Prospective Study of Comprehensive Genomic Testing in Patients With Metastatic Castration-Resistant Prostate Cancer.

Radiochemistry and comparative in vitro assessment of PSMA-617 labeled with lead-212 (212Pb), actinium-225 (225Ac), and lutetium-177 (177Lu).

Failure of a LHRH agonist in metastatic prostate cancer: a case report and review of literature.

Active surveillance for intermediate risk prostate cancer: the Manitoba Prostate Center experience.

The predictive role of [177Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary bicentric lesion-based analysis.

GMP-compliant automated synthesis and quality control of [177Lu]Lu-PSMA-I&T using the GAIA/LUNA Elysia-Raytest module for the treatment of metastatic castration-resistant prostate cancer.

Marital status and post-radical prostatectomy outcomes: results from the SEARCH database.

From 18F-choline to prostate-specific membrane antigen PET: lessons from early multiparametric kinetic modelling in prostate cancer.

The evolving PI-RADS paradigm.

The Diagnostic Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Patients with Rising PSA After Radical Prostatectomy and Postoperative Radiotherapy: A Systematic Review and Meta-analysis.

Intra-fraction target motion during MR-guided prostate stereotactic body radiotherapy: the importance of adaptive planning and real-time motion management.

Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review - Beyond the Abstract

Identification of Biomarkers Predictive of Successful Salvage Surgery in Prostate-specific Membrane Antigen Positron Emission Tomography-positive Oligorecurrent Prostate Cancer: Results from the BioPoP Trial - Beyond the Abstract

Phase II Trial of Combination Radiation, Hormone, and Immunotherapy in Grade Group 5 Prostate Cancer - Beyond the Abstract

Therapeutic Targeting of Prostate-Specific Membrane Antigen Could Limit Its Potential as Benchmark Imaging - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC